Considering the fact that the presence of tumor-specific CD8 T-cell responses almost always correlate with positive patient outcomes (3), the ultimate goal of most of these immunotherapies primarily focuses on establishing anti-tumor T-cell immunity (3, 4, 7). This evidence concerns the gene CD8A and neoplasm.